Carcinosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MMMT MCID: CRC021 MIFTS: 65	Carcinosarcoma (MMMT) Categories: Cancer diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma ¹¹ ¹⁹ ⁵³ ⁴³ ¹⁴ ⁷¹ ⁷⁵

Mixed Tumor, Mullerian ¹⁹ ⁴³ ⁷¹

Malignant Mixed Mesodermal Tumor ¹¹ ⁷¹

Malignant Mixed Mullerian Tumor ¹¹ ¹⁹

Mixed Tumor, Mesodermal ⁴³ ¹⁶

Mmmt ¹¹ ¹⁹

Mixed Tumor, Not Otherwise Specified ⁷¹

Malignant Mixed Müllerian Tumor ⁷⁵

Mixed Mesodermal Tumor ¹¹

Mesodermal Mixed Tumor ¹¹

Mullerian Mixed Tumor ¹¹

Mixed Mullerian Tumor ¹⁹

Mixed Müllerian Tumor ⁷⁵

Mixed Tumor Mullerian ⁵³

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4236

MeSH ⁴³ D002296 D018199 D018200

NCIt ⁴⁹ C34448 C3730 C8975

SNOMED-CT ⁶⁸ 112684005 63264007 84427001

EFO ¹⁶ EFO_1001371

UMLS ⁷¹ C0007140 C0206627 C1334603 more

Sources

Summaries for Carcinosarcoma

GARD: ¹⁹ Malignant mixed Mullerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary: Carcinosarcoma, also known as mixed tumor, mullerian, is related to fallopian tube carcinosarcoma and cervical carcinosarcoma. An important gene associated with Carcinosarcoma is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Coenzyme M and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and cervix, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Disease Ontology: ¹¹ A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia ⁷⁵ Carcinosarcoma: Carcinosarcomas are malignant tumors that consist of a mixture of carcinoma (or epithelial cancer) and... more...

Malignant mixed müllerian tumor: A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Sources

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 965)

#	Related Disease	Score	Top Affiliating Genes
1	fallopian tube carcinosarcoma	32.2	WT1 TP53 CALB2
2	cervical carcinosarcoma	32.2	MME CALB2
3	ovarian carcinosarcoma	32.0	WT1 TP53 PIK3CA KRAS HRAS ERBB2
4	ovarian mesodermal adenosarcoma	31.8	WT1 KRT7
5	cervical adenosarcoma	31.4	WT1 TP53 PGR MME
6	chondrosarcoma	31.4	VIM S100A1 MUC1 DES
7	adenosarcoma	31.3	VIM TP53 PGR MME KIT ERBB2
8	blastoma	31.3	TP53 KRT7 KRAS KIT HRAS EGFR
9	lung sarcomatoid carcinoma	31.3	KRT7 KRAS HRAS EGFR CALB2
10	uterine carcinosarcoma	31.1	VIM TP53 PTEN PIK3CA KRAS KIT
11	uterine sarcoma	30.9	MME KIT DES
12	vaginal carcinosarcoma	30.8	TP53 PIK3CA MME KRT7 KRAS HRAS
13	fibrosarcoma	30.8	VIM TP53 KIT EGFR DES ACTC1
14	spindle cell sarcoma	30.8	VIM TP53 MUC1 KRT7 KIT DES
15	transitional cell carcinoma	30.7	TP53 PTEN KRT7 ERBB2 EGFR
16	pleomorphic adenoma	30.7	VIM TP53 S100A1 MUC1 ERBB2 DES
17	fibrous histiocytoma	30.7	VIM MME DES ACTC1
18	bizarre leiomyoma	30.6	TP53 PGR KIT
19	endometriosis	30.6	TP53 PTEN PGR CALB2
20	bladder adenocarcinoma	30.6	TP53 KRT7 CTNNB1
21	endodermal sinus tumor	30.6	VIM KRT7 KIT
22	malignant fibrous histiocytoma	30.6	VIM TP53 S100A1 MUC1 KIT DES
23	small cell carcinoma	30.6	TP53 PTEN KRT7 EGFR
24	cutaneous fibrous histiocytoma	30.6	S100A1 MME DES ACTC1
25	basaloid squamous cell carcinoma	30.6	TP53 KRT7 KIT
26	cholecystitis	30.5	TP53 MUC1 EGFR
27	benign teratoma	30.5	TP53 KRT7 CALB2
28	atypical polypoid adenomyoma	30.5	MME CTNNB1
29	mesenchymal cell neoplasm	30.5	TP53 MME KIT CTNNB1
30	neuroendocrine carcinoma	30.5	PTEN PGR MUC1 KRT7 KIT
31	malignant teratoma	30.5	WT1 TP53 KIT
32	malignant spiradenoma	30.5	TP53 KRT7
33	bilateral breast cancer	30.5	TP53 PTEN PGR ERBB2
34	leiomyosarcoma	30.5	WT1 VIM TP53 S100A1 PGR MUC1
35	uterus leiomyosarcoma	30.4	PGR KIT DES ACTC1
36	krukenberg carcinoma	30.4	KRT7 CALB2
37	lung benign neoplasm	30.4	TP53 KRT7 KRAS HRAS EGFR
38	keratoacanthoma	30.4	TP53 PIK3CA EGFR CTNNB1
39	tubular adenocarcinoma	30.3	PGR MUC1 MME KRT7 ERBB2 CTNNB1
40	cystic teratoma	30.3	TP53 MUC1 KRT7 CALB2
41	inguinal hernia	30.3	WT1 KIT CALB2
42	appendix adenocarcinoma	30.3	TP53 KRT7 KRAS HRAS
43	skin benign neoplasm	30.3	TP53 KRT7 HRAS
44	breast metaplastic carcinoma	30.3	TP53 PGR MME KRT7 ERBB2
45	clear cell adenocarcinoma	30.3	TP53 MME KRT7
46	gallbladder adenocarcinoma	30.2	TP53 MUC1 KRT7 HRAS ERBB2
47	bronchus cancer	30.2	KRT7 ERBB2 EGFR
48	adenomyoma	30.2	PGR MUC1 MME KRT7 CTNNB1
49	benign mesothelioma	30.2	WT1 KRT7 CALB2
50	basal cell carcinoma	30.2	TP53 PTEN MUC1 MME KRT7 EGFR

Graphical network of the top 20 diseases related to Carcinosarcoma:

Sources

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

²⁵ (show all 31)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.81	EGFR HRAS KRAS PIK3CA MUC1
2	Decreased viability	GR00055-A-2	10.81	EGFR HRAS KRAS PIK3CA MUC1
3	Decreased viability	GR00055-A-3	10.81	KRAS
4	Decreased viability	GR00106-A-0	10.81	KRAS
5	Decreased viability	GR00221-A-1	10.81	EGFR HRAS KIT KRAS PIK3CA
6	Decreased viability	GR00221-A-2	10.81	HRAS KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.81	HRAS
8	Decreased viability	GR00221-A-4	10.81	EGFR PIK3CA
9	Decreased viability	GR00249-S	10.81	MUC1
10	Decreased viability	GR00301-A	10.81	KIT KRAS
11	Decreased viability	GR00381-A-1	10.81	KRAS
12	Decreased viability	GR00402-S-2	10.81	PIK3CA
13	no effect	GR00402-S-1	10.19	ACTC1 CALB2 CTNNB1 DES EGFR ERBB2
14	no effect	GR00402-S-2	10.19	ACTC1 CALB2 CTNNB1 DES EGFR ERBB2
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	9.97	VIM
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.97	KRAS
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.97	FBXW7
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.97	FBXW7
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.97	VIM
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	9.97	FBXW7
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	9.97	VIM
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	9.97	KRAS
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.97	CTNNB1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.97	FBXW7
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.97	PIK3CA
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.97	KRAS VIM
27	Increased cell migration	GR00055-A-1	9.67	CTNNB1
28	Increased cell migration	GR00055-A-3	9.67	CTNNB1
29	Increased cell death in HCT116 cells	GR00103-A-0	9.5	CTNNB1 FBXW7 PIK3CA
30	Reduced mammosphere formation	GR00396-S	9.5	DES EGFR HRAS KRAS KRT7 PTEN
31	Decreased viability in pancreas lineage	GR00235-A	9.43	KRT7 PGR TP53

MGI Mouse Phenotypes related to Carcinosarcoma:

⁴⁵ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.53	ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
2	normal	MP:0002873	10.51	ACTC1 CALB2 CTNNB1 EGFR ERBB2 FBXW7
3	muscle	MP:0005369	10.45	ACTC1 CTNNB1 DES EGFR ERBB2 HRAS
4	nervous system	MP:0003631	10.44	ACTC1 CALB2 CTNNB1 EGFR ERBB2 FBXW7
5	neoplasm	MP:0002006	10.42	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
6	cellular	MP:0005384	10.41	ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
7	cardiovascular system	MP:0005385	10.36	ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
8	endocrine/exocrine gland	MP:0005379	10.35	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
9	behavior/neurological	MP:0005386	10.31	ACTC1 CALB2 CTNNB1 DES ERBB2 HRAS
10	no phenotypic analysis	MP:0003012	10.3	CTNNB1 EGFR HRAS KIT KRAS MUC1
11	embryo	MP:0005380	10.3	CTNNB1 EGFR ERBB2 FBXW7 KIT KRAS
12	liver/biliary system	MP:0005370	10.27	CTNNB1 EGFR FBXW7 KIT KRAS MME
13	digestive/alimentary	MP:0005381	10.25	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
14	renal/urinary system	MP:0005367	10.24	CTNNB1 EGFR HRAS KIT KRAS KRT7
15	immune system	MP:0005387	10.18	CTNNB1 EGFR FBXW7 KIT KRAS MME
16	limbs/digits/tail	MP:0005371	10.16	CTNNB1 EGFR ERBB2 KIT KRAS PGR
17	respiratory system	MP:0005388	10.15	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
18	craniofacial	MP:0005382	10.1	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT
19	reproductive system	MP:0005389	10.1	CTNNB1 EGFR ERBB2 FBXW7 KIT KRAS
20	pigmentation	MP:0001186	10.09	CTNNB1 EGFR KIT KRAS PTEN TP53
21	skeleton	MP:0005390	9.96	CTNNB1 EGFR ERBB2 HRAS KIT KRAS
22	vision/eye	MP:0005391	9.85	CTNNB1 EGFR FBXW7 KIT KRAS MUC1
23	mortality/aging	MP:0010768	9.83	ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
24	integument	MP:0010771	9.44	CTNNB1 EGFR ERBB2 FBXW7 HRAS KIT

Sources

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Niraparib

Approved, Investigational

Phase 2, Phase 3

1038915-60-4

24958200

Pertuzumab

Approved

Phase 2, Phase 3

380610-27-5

Trastuzumab

Approved, Investigational

Phase 2, Phase 3

180288-69-1

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Liposomal doxorubicin

Phase 2, Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Fulvestrant

Approved, Investigational

Phase 1, Phase 2

129453-61-8

17756771 104741

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Aldesleukin

Approved

Phase 2

110942-02-4

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Olaparib

Approved

Phase 2

763113-22-0

23725625

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Rucaparib

Approved, Investigational

Phase 2

283173-50-2

9931954

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

59-30-3

6037

Iniparib

Investigational

Phase 2

160003-66-7

9796068

Saracatinib

Investigational

Phase 2

379231-04-6

10302451

Rivoceranib

Investigational

Phase 2

811803-05-1

11315474

Exatecan

Investigational

Phase 1, Phase 2

171335-80-1

18546929 151115

Interventional clinical trials:

(show top 50) (show all 90)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus	Completed	NCT00002546	Phase 3	cisplatin;ifosfamide
2	A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus	Completed	NCT00003128	Phase 3	ifosfamide;paclitaxel
3	A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy	Recruiting	NCT03651206	Phase 2, Phase 3	Niraparib;Chemotherapy Drugs
4	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	Recruiting	NCT05256225	Phase 2, Phase 3	Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
5	A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary	Active, not recruiting	NCT00954174	Phase 3	Carboplatin;Ifosfamide;Paclitaxel
6	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
7	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
8	A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas	Completed	NCT00390234	Phase 2	ziv-aflibercept
9	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
10	Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)	Completed	NCT02993705	Phase 2	Trabectedin
11	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
12	A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00687687	Phase 2	paclitaxel;carboplatin;BSI-201 (Iniparib)
13	A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00112489	Phase 2	carboplatin;paclitaxel
14	A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00025506	Phase 2	Thalidomide
15	A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma	Completed	NCT00238121	Phase 2	sorafenib tosylate
16	A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00114218	Phase 2	Gemcitabine Hydrochloride;Docetaxel
17	A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00075400	Phase 2	imatinib mesylate
18	A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma	Completed	NCT03395080	Phase 2	Paclitaxel;300mg DKN-01;600mg DKN-01
19	A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01247571	Phase 2	Pazopanib Hydrochloride
20	A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01168232	Phase 2	Ixabepilone
21	Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors	Completed	NCT00815945	Phase 2	PegLiposomal Doxorubicin;Carboplatin
22	A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma	Completed	NCT00659360	Phase 2	saracatinib
23	Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer	Completed	NCT00511992	Phase 2	Avastin;Paclitaxel;Cisplatin
24	A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas	Completed	NCT00245102	Phase 2	sorafenib tosylate
25	A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus	Completed	NCT00476086	Phase 2	Gemcitabine;Oxaliplatin
26	A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus	Completed	NCT00502203	Phase 2	Carboplatin;Paclitaxel
27	A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors	Completed	NCT00520013	Phase 2	bevacizumab;erlotinib;paclitaxel;carboplatin
28	A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors	Completed	NCT00231842	Phase 2	Ifosfamide;Cisplatin
29	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
30	A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas	Recruiting	NCT05147558	Phase 2	Pembrolizumab;Lenvatinib
31	A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma	Recruiting	NCT05265793	Phase 2	Camrelizumab Combined With Apatinib
32	A Phase II Trial of Nivolumab for Recurrent/Metastatic Carcinosarcoma	Recruiting	NCT05224999	Phase 2	nivolumab
33	A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Recruiting	NCT03668340	Phase 2	AZD1775
34	A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers	Recruiting	NCT05156268	Phase 2	Pembrolizumab;Olaparib
35	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors	Recruiting	NCT05252416	Phase 1, Phase 2	BLU-222;Carboplatin;Ribociclib;Fulvestrant
36	Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors	Recruiting	NCT05001282	Phase 1, Phase 2	ELU001
37	Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -	Recruiting	NCT02203760	Phase 2	Pazopanib plus Gemcitabine;Pazopanib
38	Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	Recruiting	NCT03449108	Phase 2	Cyclophosphamide;Fludarabine
39	A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)	Recruiting	NCT04513665	Phase 2	ZW25
40	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
41	A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma	Active, not recruiting	NCT03015129	Phase 2	Durvalumab;Tremelimumab
42	An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Active, not recruiting	NCT03648489	Phase 2	Paclitaxel;TAK228
43	A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Active, not recruiting	NCT02101775	Phase 2	Adavosertib;Gemcitabine Hydrochloride
44	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
45	An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma	Active, not recruiting	NCT03694262	Phase 2	Rucaparib;Bevacizumab;Atezolizumab
46	A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)	Active, not recruiting	NCT04106414	Phase 2	Nivolumab;BMS- 986205
47	A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.	Active, not recruiting	NCT03570437	Phase 2	Paclitaxel;Cediranib;Olaparib
48	Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	Active, not recruiting	NCT03610490	Phase 2	Cyclophosphamide;Fludarabine
49	Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff	Active, not recruiting	NCT04802876	Phase 2	Spartalizumab
50	Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer	Active, not recruiting	NCT03241745	Phase 2	Nivolumab

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Sources

Genetic Tests for Carcinosarcoma

Sources

Anatomical Context for Carcinosarcoma

Organs/tissues related to Carcinosarcoma:

MalaCards : Uterus, Smooth Muscle, Cervix, Skeletal Muscle, Colon, Pancreas, Bone

Sources

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 4591)

#	Title	Authors	PMID	Year
1	Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. ⁵³ ⁶²	Huh WK...Birrer MJ	20189232	2010
2	Intraductal carcinosarcoma with a heterologous mesenchymal component originating in intraductal papillary-mucinous carcinoma (IPMC) of the pancreas with both carcinoma and osteosarcoma cells arising from IPMC cells. ⁵³ ⁶²	Okamura J...Hiraoka N	20203229	2010
3	Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. ⁵³ ⁶²	Huang GS...Goldberg GL	19200930	2009
4	Carcinosarcoma of the gallbladder producing alpha-fetoprotein and manifesting as leukocytosis with elevated serum granulocyte colony-stimulating factor: report of a case. ⁵³ ⁶²	Shimada K...Tanaka Y	19280285	2009
5	Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. ⁵³ ⁶²	Reid-Nicholson M...Soslow RA	16648864	2006
6	Carcinosarcoma of the liver producing granulocyte-colony stimulating factor. ⁵³ ⁶²	Aita K...Seki K	16792552	2006
7	EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. ⁵³ ⁶²	Livasy CA...Lininger RA	16157366	2006
8	Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. ⁵³ ⁶²	Andreadis D...Barbatis C	16140564	2006
9	Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. ⁵³ ⁶²	Gutjahr MC...Niggli V	15950966	2005
10	Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. ⁵³ ⁶²	Caudell JJ...Ramondetta LM	15894930	2005
11	Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. ⁵³ ⁶²	Ikeda K...Mitsuya T	15863125	2005
12	HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. ⁵³ ⁶²	Raspollini MR...Taddei GL	15901136	2005
13	ERBB-2 gene overexpression and amplification in uterine sarcomas. ⁵³ ⁶²	Amant F...Vergote I	15581967	2004
14	Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. ⁵³ ⁶²	Nakatani Y...Mark EJ	15223963	2004
15	Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. ⁵³ ⁶²	Rossi G...Brambilla E	12604887	2003
16	Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. ⁵³ ⁶²	Mikami Y...Manabe T	12218209	2002
17	Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. ⁵³ ⁶²	Jazaeri AA...Rice LW	11687977	2001
18	Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. ⁵³ ⁶²	Dandachi N...Wirl G	11180164	2001
19	Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. ⁵³ ⁶²	Gilcrease MZ...Albores-Saavedra J	9786352	1998
20	Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. ⁵³ ⁶²	Schammel DP...Tavassoli FA	9500227	1998
21	Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. ⁵³ ⁶²	Sak SD...Ozdiler E	9313326	1997
22	Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. ⁵³ ⁶²	Zimmermann A...Keller H	1457347	1992
23	Immunohistochemical study of the histogenesis of esophageal carcinosarcoma. ⁵³ ⁶²	Wang ZY...Kato H	1283991	1992
24	Thymic carcinosarcoma associated with a spindle cell thymoma: an immunohistochemical study. ⁵³ ⁶²	Suarez Vilela D...Riera Velasco JR	1398523	1992
25	Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. ⁵³ ⁶²	Costa MJ...Judd R	1612579	1992
26	Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. ⁵³ ⁶²	Riviere A...Loning T	1672262	1991
27	Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. ⁵³ ⁶²	Zenklusen HR...Mihatsch MJ	2201434	1990
28	An immunohistological comparison of primary lung carcinosarcoma and sarcoma. ⁵³ ⁶²	Cupples J...Wright J	1696005	1990
29	Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. ⁶²	Ho GY...Barker HE	36206301	2022
30	A look towards the clonal origin of metastatic pulmonary carcinosarcoma: Report of a patient with an unexpected long-term survival. ⁶²	Spagnoli L...Ambrosio MR	35168438	2022
31	Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common POLE Mutation to Endometrial Endometroid Carcinoma: A Case Report. ⁶²	Kitazono I...Tanimoto A	35360975	2022
32	Primary Cutaneous Carcinosarcoma Treated With Mohs Micrographic Surgery in a Hospice Patient. ⁶²	Venishetty N...Nijhawan RI	36449880	2022
33	Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma. ⁶²	McEachron J...Lee YC	36343971	2022
34	Transanal total mesorectal excision for primary rectovaginal carcinosarcoma: A case report and literature review. ⁶²	Onishi T...Murakami T	36369664	2022
35	Carcinosarcoma of the esophago-gastric junction-a case description. ⁶²	Wlodarczyk J...Rudnicka-Sosin L	36330176	2022
36	Morphological and Immunohistochemical Characterization of an Oral Metastatic Carcinosarcoma in a Cat. ⁶²	Malatesta D...Petrini A	36265216	2022
37	Sinonasal carcinosarcoma with cartilaginous and rhabdomyoblastic components: A previously undescribed entity. ⁶²	Bartram J...Cottom H	35595621	2022
38	Merkel Cell Carcinosarcoma With a Bland Sarcomatous Component. ⁶²	Ireland AM...Mesbah Ardakani N	36075572	2022
39	Mesonephric-like Carcinosarcoma of the Uterine Corpus: Clinicopathological, Molecular and Prognostic Characteristics in Comparison With Uterine Mesonephric-like Adenocarcinoma and Conventional Endometrial Carcinosarcoma. ⁶²	Park S...Kim HS	36316041	2022
40	Impact of lymph node staging in presumed early-stage ovarian carcinoma. ⁶²	Rodrigues Teixeira F...Baiocchi G	36108452	2022
41	Alternative Lengthening of Telomeres in Primary Hepatic Neoplasms. ⁶²	Yasir S...Torbenson M	36370823	2022
42	Small Cell and Other Rare Histologic Types of Cervical Cancer. ⁶²	Marchocki Z...Covens A	35947285	2022
43	Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events. ⁶²	Zhang X...Liang G	36470146	2022
44	Radical abdomino-pelvic surgery in the management of uterine carcinosarcoma with concomitant para-aortic lymphadenopathy metastasising from anal carcinoma. ⁶²	Cowdell I...Soleymani Majd H	36450419	2022
45	Carcinoma ex-pleomorphic adenoma of mandible: A case report and review of literature. ⁶²	Ghaloo SK...Hussain RT	36274292	2022
46	Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements. ⁶²	Ihrler S...Agaimy A	36376255	2022
47	Feline uterine carcinosarcoma infiltrated with osteoclast-like giant cells. ⁶²	Murakami M...Sakai H	36261364	2022
48	Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. ⁶²	Kurnit KC...Soliman PT	36243601	2022
49	Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature. ⁶²	Aoki M...Matsumura N	36186232	2022
50	Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma. ⁶²	Ohtaki Y...Shirabe K	35848137	2022

Sources

Genes for Carcinosarcoma

Genes related to Carcinosarcoma (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	VIM	Vimentin	Protein Coding	32.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1284388 1696005 18281472 (more) 15132766 1283991 9786352 1612579 11180164 15863125
2	PGR	Progesterone Receptor	Protein Coding	26.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16648864 19200930 9313326 (more) 11687977 16580307
3	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	26.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15894930 14529656 20189232 (more) 16306788 16140564 17049587 17367465
4	TP53	Tumor Protein P53	Protein Coding	23.99	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
5	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	22.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1612579 9786352 1398523 (more) 15863125
6	KRT7	Keratin 7	Protein Coding	22.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12604887
7	PTEN	Phosphatase And Tensin Homolog	Protein Coding	22.27	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	22.08	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	21.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16157366 1672262 15581967 (more) 16405663 8630962 15901136
10	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	20.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20203229
11	MME	Membrane Metalloendopeptidase	Protein Coding	20.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12218209
12	DES	Desmin	Protein Coding	20.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1398523 1283991 1612579 (more) 16792552
13	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	20.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18281472 9500227
14	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	19.46	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
15	CTNNB1	Catenin Beta 1	Protein Coding	19.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15223963
16	S100A1	S100 Calcium Binding Protein A1	Protein Coding	15.3	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1612579
17	EGFR	Epidermal Growth Factor Receptor	Protein Coding	14.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	CALB2	Calbindin 2	Protein Coding	14.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	WT1	WT1 Transcription Factor	Protein Coding	13.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	13.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	CDH1	Cadherin 1	Protein Coding	13.91	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	13.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	PAX8	Paired Box 8	Protein Coding	13.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	CEACAM3	CEA Cell Adhesion Molecule 3	Protein Coding	13.78	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1696005 2201434 1612579
25	SYP	Synaptophysin	Protein Coding	13.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	13.71	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
27	MB	Myoglobin	Protein Coding	13.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	CD274	CD274 Molecule	Protein Coding	13.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	MMP7	Matrix Metallopeptidase 7	Protein Coding	13.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15863125

Sources

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

⁸ (show top 50) (show all 37170)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM142838165	TP53	cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.797G>A	p.G266E	17:7673823-7673823	5
2	COSM144013119	TP53	cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.698G>A	p.G233D	17:7674232-7674232	5
3	COSM122733885	TP53	cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.335G>A	p.G112D	17:7674232-7674232	5
4	COSM106054488	TP53	cervix,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.797G>A	p.G266E	17:7673823-7673823	5
5	COSM134704780	KRAS	pancreas,NS,carcinoma,carcinosarcoma	c.100C>T	p.P34S	12:25245285-25245285	5
6	COSM91938726	KRAS	pancreas,NS,carcinoma,carcinosarcoma	c.100C>T	p.P34S	12:25245285-25245285	5
7	COSM135063814	KRAS	pancreas,NS,carcinoma,carcinosarcoma	c.100C>T	p.P34S	12:25245285-25245285	5
8	COSM87892689	KRAS	pancreas,NS,carcinoma,carcinosarcoma	c.100C>T	p.P34S	12:25245285-25245285	5
9	COSM90140159	TRAF7	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.1732G>A	p.E578K	16:2175939-2175939	4
10	COSM144158749	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.512T>A	p.L171H	17:7673539-7673539	4
11	COSM144315379	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.287G>A	p.C96Y	17:7675208-7675208	4
12	COSM111836164	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.423C>T	p.C141=	17:7675189-7675189	4
13	COSM144651337	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.616G>A	p.G206S	17:7674230-7674230	4
14	COSM142559914	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.407G>A	p.R136H	17:7675088-7675088	4
15	COSM145019014	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.598A>G	p.N200D	17:7674248-7674248	4
16	COSM122762842	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.94A>G	p.K32E	17:7675122-7675122	4
17	COSM87900846	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.380C>T	p.S127F	17:7675232-7675232	4
18	COSM121875541	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.422G>A	p.R141H	17:7673802-7673802	4
19	COSM122734335	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.337G>A	p.G113S	17:7674230-7674230	4
20	COSM87898527	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.814G>A	p.V272M	17:7673806-7673806	4
21	COSM144658149	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.287G>A	p.C96Y	17:7675208-7675208	4
22	COSM143944147	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.265C>T	p.R89W	17:7674221-7674221	4
23	COSM144148837	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.-55C>T	p.?	17:7675189-7675189	4
24	COSM143158810	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.-98C>T	p.?	17:7675232-7675232	4
25	COSM105654789	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.490A>G	p.K164E	17:7675122-7675122	4
26	COSM143943941	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.337G>A	p.V113M	17:7673806-7673806	4
27	COSM143156843	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.266G>A	p.R89Q	17:7674220-7674220	4
28	COSM87897711	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.818G>A	p.R273H	17:7673802-7673802	4
29	COSM121876485	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.421C>T	p.R141C	17:7673803-7673803	4
30	COSM142837497	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.733G>A	p.G245S	17:7674230-7674230	4
31	COSM122299085	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.94A>G	p.K32E	17:7675122-7675122	4
32	COSM121876255	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.315G>A	p.M105I	17:7674252-7674252	4
33	COSM143370575	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.701G>A	p.R234H	17:7673802-7673802	4
34	COSM111758775	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.733G>A	p.G245S	17:7674230-7674230	4
35	COSM106053434	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.742C>T	p.R248W	17:7674221-7674221	4
36	COSM112282360	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.490A>G	p.K164E	17:7675122-7675122	4
37	COSM144087235	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.234G>A	p.M78I	17:7674252-7674252	4
38	COSM143371076	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.616G>A	p.G206S	17:7674230-7674230	4
39	COSM106080940	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.490A>G	p.K164E	17:7675122-7675122	4
40	COSM106124583	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.423C>T	p.C141=	17:7675189-7675189	4
41	COSM144015546	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.347C>T	p.S116F	17:7675232-7675232	4
42	COSM142846805	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.725G>C	p.C242S	17:7674238-7674238	4
43	COSM142560476	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.616G>A	p.G206S	17:7674230-7674230	4
44	COSM121876163	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.418G>A	p.V140M	17:7673806-7673806	4
45	COSM143372002	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.598A>G	p.N200D	17:7674248-7674248	4
46	COSM144311239	TP53	lung,NS,carcinoma,carcinosarcoma	c.680G>A	p.G227E	17:7673823-7673823	4
47	COSM144091376	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.-74G>A	p.?	17:7675208-7675208	4
48	COSM122277699	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.8G>A	p.C3Y	17:7675208-7675208	4
49	COSM112327118	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.423C>T	p.C141=	17:7675189-7675189	4
50	COSM145024439	TP53	ovary,NS,carcinoma,carcinosarcoma-malignant mesodermal mixed tumour	c.287G>A	p.C96Y	17:7675208-7675208	4

Sources

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Sources

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 97)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.03	VIM TP53 S100A1 PTEN PIK3CA MUC1
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.87	VIM TP53 PTEN MUC1 KRAS KIT
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.83	TP53 S100A1 PTEN PIK3CA MUC1 KRAS
4	Signal Transduction ⁶⁶	13.78	VIM TP53 PTEN PIK3CA PGR KRAS
5	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.53	TP53 PTEN PIK3CA KRAS HRAS ERBB2
6	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.46	TP53 PTEN KRAS KIT HRAS ERBB2
7	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.42	PTEN PIK3CA KRAS KIT HRAS FBXW7
8	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.35	PTEN KRAS KIT HRAS ERBB2 EGFR
9	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.33	CTNNB1 EGFR ERBB2 HRAS KIT KRAS
10	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.12	TP53 PTEN PIK3CA KIT ERBB2 EGFR
11	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.12	TP53 PTEN KRAS KIT HRAS EGFR
12	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.01	TP53 PTEN PIK3CA KRAS KIT HRAS
13	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.93	PTEN PIK3CA KRAS HRAS ERBB2 EGFR
14	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.89	PIK3CA MME KRAS HRAS CTNNB1
15	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.89	PIK3CA KRAS KIT HRAS EGFR
16	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.89	CTNNB1 EGFR ERBB2 HRAS KIT KRAS
17	DREAM Repression and Dynorphin Expression ⁶⁴ Show member pathways Arrhythmogenic right ventricular cardiomyopathy ⁷⁴ BMP Pathway ⁶⁴ Calpain Protease Regulates Cellular Mechanics ⁶⁴ Caspase Cascade ⁶⁴ nNOS Signaling in Skeletal Muscle ⁶⁴ Presynaptic depolarization and calcium channel opening ⁶⁶ TOB in Osteoblast Signaling ⁶⁴	12.83	KRAS HRAS EGFR DES CTNNB1
18	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.74	PTEN PIK3CA KIT ERBB2 EGFR
19	Malignant pleural mesothelioma ⁷⁴	12.71	TP53 PTEN PIK3CA KIT HRAS EGFR
20	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.7	EGFR HRAS KIT KRAS PIK3CA TP53
21	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.65	TP53 PIK3CA KRAS HRAS ERBB2 EGFR
22	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.64	TP53 PTEN PIK3CA KRAS KIT HRAS
23	Cytoskeletal Signaling ³	12.6	VIM MUC1 KRT7 DES ACTC1
24	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.53	TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
25	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.47	TP53 PIK3CA KRAS HRAS ERBB2 EGFR
26	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.46	EGFR HRAS KRAS PIK3CA
27	MAPK signaling pathway ⁷⁴	12.46	TP53 KRAS HRAS EGFR
28	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.45	PIK3CA KRAS HRAS CTNNB1
29	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.43	CTNNB1 EGFR ERBB2 HRAS KIT KRAS
30	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.38	PIK3CA HRAS ERBB2 EGFR
31	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.37	PTEN PIK3CA KRAS HRAS
32	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.37	PIK3CA KRAS HRAS CTNNB1
33	Focal adhesion ⁷⁴	12.36	PTEN PIK3CA HRAS ERBB2 EGFR CTNNB1
34	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.34	CTNNB1 EGFR ERBB2 HRAS KRAS MUC1
35	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.32	TP53 PTEN PIK3CA HRAS
36	Ras signaling ⁷⁴	12.32	EGFR HRAS KIT KRAS PIK3CA
37	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.31	PIK3CA KRAS HRAS ERBB2 EGFR
38	Development Endothelin-1/EDNRA transactivation of EGFR ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA signaling ²²	12.3	PIK3CA HRAS EGFR CTNNB1
39	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.27	PTEN KRAS HRAS EGFR
40	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.27	EGFR ERBB2 HRAS KRAS PIK3CA PTEN
41	Colorectal Cancer Metastasis ⁶⁴	12.25	TP53 KRAS EGFR CTNNB1
42	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.25	TP53 PIK3CA KRAS HRAS CTNNB1
43	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.21	KRAS HRAS ERBB2 EGFR
44	Integrated breast cancer pathway ⁷⁴	12.21	CTNNB1 EGFR KRAS PTEN TP53
45	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.2	TP53 PTEN PIK3CA HRAS
46	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.19	PTEN PIK3CA HRAS ERBB2 EGFR CTNNB1
47	mTOR Signaling ⁶⁵	12.17	TP53 PTEN KRAS ERBB2 EGFR
48	Signaling by EGFR in Cancer ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ EGFR interacts with phospholipase C-gamma ⁶⁶ EGFR-dependent Endothelin signaling events ⁶¹ GRB2 events in EGFR signaling ⁶⁶ SHC1 events in EGFR signaling ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	12.16	PIK3CA KRAS HRAS EGFR
49	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.12	PIK3CA PGR KRAS HRAS ERBB2 EGFR
50	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.11	PIK3CA KRAS HRAS ERBB2 EGFR

Sources

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.85	ACTC1 CTNNB1 DES EGFR ERBB2 FBXW7
2	focal adhesion	GO:0005925	9.73	VIM MME KRAS EGFR CTNNB1 ACTC1

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.15	PTEN KRAS KIT HRAS ERBB2 EGFR
2	negative regulation of apoptotic process	GO:0043066	10.13	ACTC1 CTNNB1 EGFR ERBB2 PTEN TP53
3	MAPK cascade	GO:0000165	10.1	KRAS HRAS EGFR CTNNB1
4	heart development	GO:0007507	10.06	WT1 TP53 PTEN ERBB2 CTNNB1
5	positive regulation of MAP kinase activity	GO:0043406	10.01	KIT HRAS ERBB2 EGFR
6	negative regulation of gene expression	GO:0010629	10	TP53 PIK3CA PGR HRAS FBXW7 CTNNB1
7	phosphatidylinositol 3-kinase signaling	GO:0014065	9.95	PTEN PIK3CA ERBB2
8	vasculature development	GO:0001944	9.83	CTNNB1 FBXW7 PIK3CA
9	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.81	TP53 MUC1
10	cell population proliferation	GO:0008283	9.63	TP53 PTEN KRAS KIT EGFR CTNNB1
11	regulation of cell population proliferation	GO:0042127	9.56	CTNNB1 EGFR ERBB2 HRAS KIT TP53
12	positive regulation of gene expression	GO:0010628	9.53	WT1 VIM TP53 PGR KRAS KIT